Sort   by:  
 Page size 
TranscriptomicsUnexpected roles of ATP11B in platinum resistance
Platinum compounds display clinical activity against a wide variety of solid tumors. However, resistance to these agents is a major limitation in cancer therapy. Reduced platinum uptake and increased platinum export are examples of resistance mechanisms that limit the extent of DNA damage. Here, we ...
ORGANISM(S): Homo sapiens 
2013-01-23 | E-GEOD-43694 | biostudies-arrayexpress
TranscriptomicsTranscription profiling of human A540 non small cell carcinoma cell lines reveals synergy between PPARgamma ligands and platinum-based drugs in cancer
PPARγ is a member of the nuclear receptor family for which agonist ligands have anti-growth effects. However, clinical studies using PPARγ ligands as a monotherapy failed to show a beneficial effect. Here we have studied the effects of PPARγ activation with chemotherapeutic agents in current us...
ORGANISM(S): Homo sapiens 
2009-04-30 | E-GEOD-7035 | biostudies-arrayexpress
TranscriptomicsGenomic Multivariate Predictors of Response to Adjuvant Chemotherapy in Ovarian Carcinoma: Predicting Platinum Resistance
Purpose: Despite advances in radical surgery and chemotherapy delivery, ovarian cancer is the most lethal gynecologic malignancy. Most of these patients are treated with platinum-based chemotherapies, but there is no biomarker model to guide their responses to these therapeutic agents. We have d...
ORGANISM(S): Homo sapiens 
2012-08-21 | E-GEOD-30161 | biostudies-arrayexpress
TranscriptomicsDNA-targeted platinum-acridine anticancer agents
Yeast homozygous and essential heterozygous deletion mutants were screened against novel platinum-containing compounds
ORGANISM(S): Schizosaccharomyces pombe 
2012-08-28 | E-MTAB-1267 | biostudies-arrayexpress
TranscriptomicsGlobal profiling of platinum drugs resistant genes in A549 cell lines
Non Small Cell Lung Cancer (NSCLC) causes the premature death of over 1 million people worldwide each year, but remains inadequately understood at the molecular level. To provide new insights for NSCLC treatment we performed a molecular characterisation of wild type and platinum drugs resistance in ...
ORGANISM(S): Homo sapiens 
2012-02-24 | E-MEXP-3123 | biostudies-arrayexpress
ProteomicsIdentification of proteins deregulated by platinum-based chemotherapy as novel biomarkers and therapeutic targets in non-small cell lung cancer
Platinum-based chemotherapy remains the cornerstone of treatment for most people with non-small cell lung cancer (NSCLC), either as adjuvant therapy in combination with a second cytotoxic agent or in combination with immunotherapy. Resistance to therapy, either in the form of primary refractory dise...
ORGANISM(S): Homo Sapiens 
2021-06-15 | PXD024209 | panorama
TranscriptomicsExpression data from A2780 (cisplatin-sensitive) and Round5 A2780 (cisplatin-resistant) cell lines.
Cisplatin and carboplatin are the primary first-line therapies for the treatment of ovarian cancer. However, resistance to these platinum-based drugs occurs in the large majority of initially responsive tumors, subsequently resulting in a poor long-term prognosis. To model the onset of drug resista...
ORGANISM(S): Homo sapiens 
2009-04-17 | E-GEOD-15372 | biostudies-arrayexpress
TranscriptomicsmiRNA profiling of longitudinal ovarian cancer biopsies collected before and after platinum-based neo-adjuvant chemotherapy
In the last decades platinum-based neo-adjuvant chemotherapy (NACT) has been recognized as a reliable therapeutic strategy in patients with un-resectable advanced epithelial ovarian cancer (EOC). However, the molecular changes induced by NACT at miRNA level, and their prognostic role has not been cl...
ORGANISM(S): Homo sapiens 
2016-01-20 | E-MTAB-3696 | biostudies-arrayexpress
TranscriptomicsExpression data from cultured human ovarian carcinoma cell lines with and without Cisplatin treatment
Chemo-resistance to platinum such as cisplatin is critical in the treatment of ovarian cancer. Recent evidences have linked epithelial-mesenchymal transition (EMT) with the drug resistance as a contributing mechanism. The current study explored the connection between cellular responses to cisplatin ...
ORGANISM(S): Homo sapiens 
2014-07-29 | E-GEOD-47856 | biostudies-arrayexpress
TranscriptomicsTranscription profiling by array of mesothelioma pre- and post-resistance biopsies in order to determine a resistance signature to pemetrexed/carboplatin treatment
Pemetrexed, a multi-folate inhibitor combined with a platinum compound is the first-line treatment of malignant mesothelioma, but median survival is still one year. Innate and acquired resistance to pemetrexed is common, but its biological basis is obscure. Here we report for the first time a genome...
ORGANISM(S): Homo sapiens 
2012-10-01 | E-MTAB-1109 | biostudies-arrayexpress
Sort   by:  
 Page size